About Alteplase (tPA) Dosing

The Alteplase (tPA) Dose Calculator is a clinical tool designed for healthcare professionals to determine appropriate weight-based dosing regimens for alteplase across its major indications. This guide provides detailed information on how the calculations are derived, the outputs provided, and essential safety considerations based on current clinical guidelines.

Outputs Explained

After inputting the patient’s weight and selecting an indication, the calculator provides the following key outputs for safe and accurate administration:

• Total Dose: The complete amount of alteplase (in mg) to be administered. For acute ischemic stroke, this is capped at a maximum of 90 mg.
• Bolus Dose: The initial amount of drug (in mg) to be given as a rapid intravenous injection, typically over one minute.
• Infusion Dose: The remaining portion of the total dose to be administered as a continuous intravenous infusion over a specified time.
• Infusion Rate: The calculated rate (in mL/hr) for the infusion pump, assuming a standard concentration (e.g., 1 mg/mL).
• Amount to Waste: The volume of reconstituted drug to be discarded from the vial (typically 100 mg) to ensure the correct total dose is administered.

How to Use the Calculator

To ensure accurate dosing, follow these steps when using the tool:

1. Select Indication: Choose the appropriate clinical reason for alteplase administration from the dropdown menu (Acute Ischemic Stroke, STEMI, or Pulmonary Embolism).
2. Enter Patient Weight: Input the patient’s actual body weight. The calculator accepts weight in either kilograms (kg) or pounds (lbs). Ensure the correct unit is selected.
3. Review Results: The tool automatically calculates and displays the full dosing regimen. Always double-check these results against institutional protocols and the patient’s clinical status before administration.

Dosing Overview

Acute Ischemic Stroke (AIS)

The standard dosing for AIS is 0.9 mg/kg of actual body weight. The total dose should not exceed 90 mg. The administration is split as follows:

• 10% of the total dose is given as an IV bolus over 1 minute.
• The remaining 90% is infused IV over 60 minutes.

ST-Elevation Myocardial Infarction (STEMI)

An accelerated infusion regimen is used for STEMI, with dosing adjusted for patient weight:

• For patients > 67 kg: A total dose of 100 mg is administered as a 15 mg IV bolus, followed by 50 mg infused over 30 minutes, and then 35 mg infused over the next 60 minutes.
• For patients ≤ 67 kg: A weight-based dose is given as a 15 mg IV bolus, followed by 0.75 mg/kg (up to 50 mg) over 30 minutes, and then 0.5 mg/kg (up to 35 mg) over the next 60 minutes.

Pulmonary Embolism (PE)

For massive pulmonary embolism, the standard regimen is not weight-based. A total dose of 100 mg is administered as a continuous IV infusion over 2 hours.

Switching to Anticoagulants

After alteplase therapy, transitioning to an anticoagulant is crucial to prevent re-thrombosis. The timing depends on the indication and agent chosen. For AIS, anticoagulant or antiplatelet therapy is typically delayed for 24 hours pending a follow-up CT scan to rule out intracranial hemorrhage. Always consult specific guidelines for post-thrombolysis management.

Missed Dose Protocol

Alteplase is administered as a single, time-critical treatment regimen for acute thrombotic events. The concept of a “missed dose” does not apply. Adherence to the initial bolus and infusion protocol is critical for efficacy and safety. Any interruption in the infusion should be addressed immediately according to institutional guidelines.

Safety Alerts and Contraindications

Alteplase administration carries a significant risk of bleeding. A thorough risk-benefit assessment and screening for contraindications are mandatory before use. The primary risk is intracranial hemorrhage (ICH), but serious systemic bleeding can also occur.

Frequently Asked Questions (FAQ)

What is the maximum dose of alteplase for ischemic stroke?

The maximum total dose of alteplase for the treatment of acute ischemic stroke is strictly capped at 90 mg, regardless of the patient’s weight.

Does the dosing for pulmonary embolism (PE) depend on patient weight?

No, the standard FDA-approved regimen for PE is a fixed dose of 100 mg infused over 2 hours and is not adjusted for the patient’s weight.

Why is medication wasted from the 100 mg vial for stroke patients?

Since the stroke dose is calculated at 0.9 mg/kg (max 90 mg), most adult patients will require less than the 100 mg available in a standard vial. The excess reconstituted drug must be carefully measured and wasted to ensure the precise dose is administered.

What vital signs must be monitored during and after tPA infusion?

Neurological assessments and blood pressure should be monitored frequently, typically every 15 minutes for the first 2 hours, then every 30 minutes for 6 hours, then hourly for 16 hours. Close monitoring for signs of bleeding, angioedema, or neurological decline is critical.

How is alteplase reconstituted?

Alteplase (lyophilized powder) must be reconstituted with Sterile Water for Injection, USP, without preservatives. The manufacturer’s specific instructions for reconstitution to achieve a 1 mg/mL concentration must be followed precisely.

Can alteplase be administered if a patient is on an anticoagulant?

Recent use of anticoagulants (e.g., warfarin, DOACs) is a relative or absolute contraindication, depending on the agent, timing of the last dose, and coagulation lab values (e.g., INR, aPTT). Consult guidelines, as specific reversal agents or tests may be required.

What is the “door-to-needle” time goal for alteplase in stroke?

For eligible patients with acute ischemic stroke, national guidelines recommend a “door-to-needle” (hospital arrival to alteplase administration) time of 60 minutes or less, with many centers striving for 45 or even 30 minutes.

Are there alternatives to alteplase for ischemic stroke?

Tenecteplase (TNK) is emerging as an alternative to alteplase for AIS, particularly for large vessel occlusions prior to endovascular therapy. It is administered as a single, weight-based bolus, simplifying administration. Check institutional protocols for its availability and use.

References

• Activase (Alteplase) Prescribing Information. U.S. Food and Drug Administration.
• Powers WJ, et al. (2019). 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke.
• Jaff MR, et al. (2011). Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. Circulation.
• O’Gara PT, et al. (2013). 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation.